NeuroOne Medical Technologies Files 8-K
Ticker: NMTC · Form: 8-K · Filed: Feb 4, 2025 · CIK: 1500198
| Field | Detail |
|---|---|
| Company | Neuroone Medical Technologies CORP (NMTC) |
| Form Type | 8-K |
| Filed Date | Feb 4, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, medical-devices
TL;DR
NeuroOne Medical Technologies filed an 8-K on Feb 4, 2025, for events on Feb 3, 2025.
AI Summary
NeuroOne Medical Technologies Corporation filed an 8-K on February 4, 2025, reporting on events that occurred on February 3, 2025. The filing indicates the company is a medical device manufacturer incorporated in Delaware, with its principal executive offices located in Eden Prairie, MN.
Why It Matters
This 8-K filing serves as a public record of significant corporate events for NeuroOne Medical Technologies, providing transparency to investors and stakeholders.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain information that inherently increases risk.
Key Numbers
- 001-40439 — SEC File Number (Identifies the company's filing with the SEC.)
- 27-0863354 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- NeuroOne Medical Technologies Corporation (company) — Registrant
- February 3, 2025 (date) — Earliest Event Reported
- February 4, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Eden Prairie, MN (location) — Principal Executive Offices
FAQ
What is the primary business of NeuroOne Medical Technologies Corporation?
NeuroOne Medical Technologies Corporation is involved in the manufacturing of surgical and medical instruments and apparatus, as indicated by its SIC code 3841.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 3, 2025.
What is the company's fiscal year end?
The company's fiscal year ends on September 30 (0930).
Where are NeuroOne Medical Technologies Corporation's principal executive offices located?
The principal executive offices are located at 7599 Anagram Dr., Eden Prairie, MN 55344.
What is the SEC file number for NeuroOne Medical Technologies Corporation?
The SEC file number for NeuroOne Medical Technologies Corporation is 001-40439.
Filing Stats: 475 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-02-04 16:15:21
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share NMTC The Nasdaq Stock Mar
Filing Documents
- ea0229869-8k_neuroone.htm (8-K) — 24KB
- ea022986901ex99-1_neuroone.htm (EX-99.1) — 8KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001213900-25-010083.txt ( ) — 211KB
- nmtc-20250203.xsd (EX-101.SCH) — 3KB
- nmtc-20250203_lab.xml (EX-101.LAB) — 33KB
- nmtc-20250203_pre.xml (EX-101.PRE) — 22KB
- ea0229869-8k_neuroone_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On February 3, 2025, NeuroOne Medical Technologies Corporation (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with the bid price requirement under Nasdaq Listing Rule 5550(a)(2). As a result, the Company's hearing before the hearings panel has been cancelled and the Company's common stock will remain listed on Nasdaq. On February 4, 2025, the Company issued a press release regarding Nasdaq compliance. A copy of the press release is attached hereto as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated February 4, 2025 . 104 Cover Page Interactive Data File (embedded within Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROONE MEDICAL TECHNOLOGIES CORPORATION Dated: February 4, 2025 By: /s/ David Rosa David Rosa Chief Executive Officer 2